Acura Pharmaceuticals to Host First Quarter 2013 Financial Results Conference Call on May 3, 2013
(firmenpresse) - PALATINE, IL -- (Marketwired) -- 04/22/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating , today announced that the company plans to report financial results for the first quarter of 2013 following the close of financial markets on Thursday, May 2, 2013. The company will host a conference call to discuss the results on Friday, May 3, 2013 at 8:30 a.m. ET.
To participate in the live conference call, please dial 888-427-9419 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 1259095.
A replay of the call will be available beginning May 6, 2013 at 11:30 a.m. ET and ending on May, 27, 2013 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 1259095.
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE™ technologies. In June 2011, the U.S. Food and Drug Administration approved OXECTA® which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products including other opioids and its IMPEDE™ technology for pseudoephedrine hydrochloride products.
The trademark OXECTA® is owned by Pfizer Inc.
Contact:
847-705-7709
847-705-7709
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.04.2013 - 20:15 Uhr
Sprache: Deutsch
News-ID 251507
Anzahl Zeichen: 0
contact information:
Town:
PALATINE, IL
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Acura Pharmaceuticals to Host First Quarter 2013 Financial Results Conference Call on May 3, 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Acura Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
